Plus Therapeutics stockholders approve 20x authorized share increase to 2B; massive dilution authorized

PLUS THERAPEUTICS, INC.

Authorized common shares increased from 100M to 2B; reverse split authorized at ratio between 1:25 and 1:250.
Stockholders approved issuance of up to 1.26B shares upon exercise of Series B Warrants with zero exercise price.
Warrant exercise price reset to floor of $0.132; Series A/B could total ~1.68B shares if fully exercised.
All proposals passed with >88% votes for; quorum of 8.2M shares out of 11.8M outstanding.
Item 8.01 confirms massive potential equity dilution from prior private placement warrants.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

PLUS THERAPEUTICS, INC.: Increased authorized shares of common stock from 100,000,000 to 2,000,000,000 (effective 2025-05-02).

Change: charter amendment
Effective: 2025-05-02

Exact text from the filing

the stockholders of the Company approved a Certificate of Amendment (the “Amendment”) to the Company’s Certificate of Incorporation, as amended (the “Certificate of Incorporation”), to increase the authorized shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), from 100,000,000 shares to 2,000,000,000 shares

View on SEC.gov

73 governance changes filed in the last 30 days. Browse all governance changes →

PLUS THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0000950170-25-062742

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.